# Profit and Loss

## Tuberous Sclerosis Australia
## For the year ended 30 June 2026

| | 2026 | 2025 |
|---|---|---|
| **Trading Income** | | |
| Bronze Membership Fee | 86 | 214 |
| Contributions from Members | 3,480 | 9,245 |
| Contributions from members - Bronze | 570 | 1,340 |
| Contributions from members - Platinum | - | 11,940 |
| Contributions from members - Silver | 45 | 230 |
| Corporate Giving and Partnerships | 10,000 | 5,000 |
| Donations Received | 102,842 | 100,162 |
| Gold Membership Fee | 109 | 323 |
| Grants Received | 94,097 | 47,298 |
| Interest Income | - | - |
| Interest Income - BoQ - Stockspot | - | 75 |
| Membership Fees | - | 55 |
| Other Income | - | 1,177 |
| Sales of Goods | 125 | 360 |
| Silver Membership Fee | 5 | 23 |
| **Total Trading Income** | **211,359** | **177,440** |
| **Gross Profit** | **211,359** | **177,440** |
| **Other Income** | | |
| Interest Income - NAB Trade - Cash Account x8234 | 4 | 5 |
| Interest Income - NAB Trade - HI Account x0462 | 365 | 4,969 |
| nabtrade Investment Income | - | 4,861 |
| Stockspot Investment Income | 19,642 | 11,391 |
| Stockspot Investment Income - Franking Credits | 796 | 526 |
| Stockspot Investment Income - Unrealised Market Value Gains/(Losses) | 15,594 | 13,994 |
| **Total Other Income** | **36,401** | **35,746** |
| **Operating Expenses** | | |
| Accounting Fees | 14,230 | 14,203 |
| Advertising and Promotion | 584 | - |
| Bank Charges | 412 | 614 |
| Board/Governance Expenses | 232 | 582 |
| Consultancy Fees | 21,761 | 42,000 |
| Credit Card Fees | 695 | 85 |
| Educational Event Expenses | 193 | 1,600 |
| Fundraising Event Expenses | 1,706 | - |
| Fundraising Expenses | 264 | 4 |
| Information Technology Expenses | 7,246 | 9,215 |
| Insurance Expense | 4,057 | 4,296 |
| Investment Fees - Stockspot | 1,447 | 941 |
| Membership Fees Paid | 100 | 340 |

| | 2026 | 2025 |
|---|---|---|
| Payment Gateway Fees - PayPal | 61 | 124 |
| Payment Gateway Fees - Stripe | 1,560 | 2,848 |
| Postage, Freight and Courier | 120 | 75 |
| Printing & Stationery | 172 | 14 |
| Publications and Information Resources | 1,877 | 3,721 |
| Realised Currency Gains | - | 3 |
| Salaries and Wages | 103,102 | 87,054 |
| Salaries and Wages - Accrued | 5,000 | - |
| Salaries and Wages - Annual Leave Provision | 1,186 | 1,604 |
| Salaries and Wages - Long Service Leave Provision | 5,478 | 3,910 |
| Salaries and Wages - Superannuation | 12,269 | 9,938 |
| Salaries and Wages - Superannuation - Accrued | 600 | - |
| Sundry expenses | 298 | 157 |
| Telephone and Internet | 608 | 597 |
| Travel & Accommodation | 2,892 | 3,315 |
| Volunteer Costs | 228 | - |
| **Total Operating Expenses** | **188,377** | **187,240** |
| **Net Profit** | **59,384** | **25,946** |

# Balance Sheet

## Tuberous Sclerosis Australia
## As at 30 June 2026

| | 30 JUNE 2026 | 30 JUNE 2025 |
|---|---|---|
| **Assets** | | |
| **Bank** | | |
| AUD PayPal | 1,604 | 5,531 |
| BoQ - Cash Account (Stockspot) | 755 | 625 |
| CBA Gambrell Expenses x0991 | 333 | 872 |
| CBA General Cheque - x3534 | 64,189 | 54,969 |
| NAB Trade - Cash Account x8234 | - | 1 |
| NAB Trade - HI Account x0462 | - | 103,215 |
| **Total Bank** | **66,880** | **165,214** |
| **Current Assets** | | |
| Accounts Receivables | - | 25,100 |
| Refundable - Franking Credits | 796 | 1,061 |
| **Total Current Assets** | **796** | **26,161** |
| **Non-current Assets** | | |
| Add/(Less): Stockspot - Unrealised Market Value Gains/(Losses) | 34,289 | 18,695 |
| Stockspot - Investments at Cost | 399,427 | 251,362 |
| **Total Non-current Assets** | **433,716** | **270,057** |
| **Total Assets** | **501,392** | **461,432** |
| **Liabilities** | | |
| **Current Liabilities** | | |
| Accrued Expenses | 5,600 | - |
| Grants Unexpended - AFT Pharmaceuticals | 10,000 | 10,000 |
| Grants Unexpended - Goldman Sachs Gives UK | - | 9,915 |
| Grants Unexpended - Other | - | 25,000 |
| Grants Unexpended - Sanofi | 11,500 | 12,639 |
| GST | (976) | (2,416) |
| PAYG Withholding Payable | 2,971 | 1,654 |
| Provision for Annual Leave | 18,565 | 17,380 |
| Superannuation Payable | 1,043 | 2,427 |
| Trade Creditors | 1,165 | 5,670 |
| Grants Unexpended - Jazz Pharma | 7,500 | - |
| **Total Current Liabilities** | **57,368** | **82,270** |
| **Non-current Liabilities** | | |
| Provision for Long Service Leave | 18,063 | 12,585 |
| **Total Non-current Liabilities** | **18,063** | **12,585** |
| **Total Liabilities** | **75,431** | **94,854** |
| **Net Assets** | **425,961** | **366,578** |
| **Equity** | | |

| | 30 JUNE 2026 | 30 JUNE 2025 |
|---|---|---|
| Current Year Earnings | 59,384 | 25,946 |
| Retained Surplus | 366,578 | 340,632 |
| **Total Equity** | **425,961** | **366,578** |

# Bondy Mortimer & Co

*CPA Practice*

*ABN: 81 831 046 629*

SUITE 20, 809-811 PACIFIC HIGHWAY, CHATSWOOD, NSW 2067
P.O BOX 5358, CHATSWOOD 2067
TELEPHONE: 9419 8322
EMAIL: markmortimer@bondymortimer.com.au

M.A. Mortimer
CPA


**Independent Auditor's Report to the Committee of Tuberous Sclerosis Australia Inc ABN 20 681 174 374**

**Opinion**

We have audited the financial report of Tuberous Sclerosis Australia Inc. being a Special Purpose financial report which comprises the Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June 2026, the Statement of Financial Position as at 30 June 2026, the, and the Statement of Cash Flows for the year ended 30 June 2026.

In our opinion, the accompanying financial report presents fairly, in all material respects a true and fair view of the financial position of the entity, and of its financial performance, and its cash flows for the year then ended, in accordance with Australian Accounting Standards, and the Associations Incorporation Act 2009.

The financial statements also comply with the International Reporting Standards as disclosed in the Notes to the attached Report.

**Basis for Opinion**

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the entity in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Other Information**

The Committee of Tuberous Sclerosis Australia Inc. is charged with governance and is responsible for the other information. The other information comprises the information included in the entity's annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in so doing, consider whether the other information is materially inconsistent with the financial report, or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of Management and Those Charged with Governance for the Financial Report**

The Committee is responsible for the preparation and fair presentation, of the financial report in accordance with Australian Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of the financial report that it is free of material misstatement, whether due to fraud or error,

In preparing the financial report, the committee is also responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the committee either intends to liquidate it, or cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the entity's financial reporting process.

**Auditor's Responsibility for the Audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole, is free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence economic decisions of users taken on the basis of the financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at http://www.ausab.gov.au/Home.aspx.

Furthermore, as part of an audit in accordance with the Australian Auditing Standards we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

>Identify and assess risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than one for resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

>Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.

>Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates related disclosures made by management

>Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern

>Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other things, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Signed at Chatswood this 25 September 2016

Mark Mortimer (Registered No. 1942)
Certified Practising Accountant
Bondy Mortimer & Co
20/809 Pacific Hwy Chatswood NSW 2067